Stanley TL, Fourman LT, Feldpausch MN, et al. - Given that non-alcoholic fatty liver disease (NAFLD) is an important cause of comorbidity in people with HIV, researchers examined how tesamorelin affects liver fat and histology in people with HIV and NAFLD. In this randomized, double-blind, multicentre study with identical placebo as a comparator, 61 patients with HIV infection and a hepatic fat fraction (HFF) of 5% or more were provided either tesamorelin 2 mg once daily or placebo once daily for 12 months. Following this, all participants received tesamorelin 2 mg daily during a 6-month open-label phase. Relative to patients receiving placebo, patients receiving tesamorelin showed a greater reduction of HFF. After 12 months, they observed a HFF of less than 5% in 35% of individuals receiving tesamorelin and 4% receiving a placebo. Based on these findings, people with HIV and NAFLD may benefit from receiving tesamorelin.